SOURCE: Entest BioMedical Inc.
SAN DIEGO, CA--(Marketwire - Sep 6, 2012) - Entest BioMedical Inc. (OTCQB: ENTB) a company focused on veterinary biotechnology and veterinary hospital acquisition / operation, announced today that the company's recent research study conducted on ImenVax™ (Entest's Immuno-therapeutic cancer vaccine for dogs), ImenVax™ appears to show signs of slowing tumor growth in advanced cases of oral melanoma, while being well tolerated by patients.
"Principal investigators conducting the safety study on ImenVax™ observed the implantation device and vaccine to be very well-tolerated," stated Entest BioMedical Chairman & CEO David Koos. "There was only one case where the patient had a minor skin irritation. In all of the cases studied the size of the tumors were likely too extensive to allow for objective response with ImenVax™ as single agent therapy. The company's researchers stated that subjectively, tumor progression was slowed during the period that the implant was present and accelerated after removal in 2 patients. The report recommends that further evaluation in patients with lesser tumor burden is warranted, along with cytokine stimulation."
Dr. Koos continued, "Our ImenVax™ immune-therapeutic cancer vaccine is designed to treat dogs with oral melanoma while limiting the side effects of treatment. We anticipate that within the next 16 months, we will have the capacity to treat just over 3,000 patients yearly throughout our veterinary clinics."
A Spokesperson for the Company noted the National Canine Cancer Foundation says one in three dogs will be impacted by cancer. This staggering statistic shows not only the need for a cost effective treatment but also a treatment that is well tolerated. The potential revenue generated per patient is approximately $3,000 according to industry statistics. Management indicates that each veterinary hospital Entest will seek to acquire over the next two years will have a preexisting patient flow of at least 700 cancer patients per year. Once the first 10 veterinary hospitals have been acquired, Entest could possibly see 7,000 treatable canine patients per year at $3,000 per patient. This meaning, should Entest be successful in meeting its veterinary hospital acquisition target numbers [10 facilities], the company could potentially command revenues reflecting as much as $21 million per annum; treating dogs with cancer.
Dr. Koos concluded, "Our ImenVax™ immuno-therapeutic cancer vaccine is being designed to utilize the patient's own immune system to battle the cancer; potentially making it a less invasive and less traumatic alternative for pet owners than chemotherapy and radiation therapy. Also, the safety study is being conducted on dogs suffering from oral melanoma. We have no intention to simply stop at oral melanoma applications. Entest is working with an incredibly experienced research team in hopes to increase efficacy in extreme cases by the inclusion of cytokine stimulation. We anticipate at some point in the near future, to begin clinical trials as we will ultimately seek USDA or FDA approval to further the reach of our ImenVax™ canine cancer treatment."
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCQB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.